The share transfer execution date has been changed from scheduled end of November 2026 to scheduled end of December 2026. The reason is to carefully confirm the transition process and secure sufficient preparation time. Impact on consolidated earnings guidance for the fiscal year ending March 2027 is minor; negative goodwill is expected to arise.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4553","jir_company_name":"Towa Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4553-20261030-01.pdf","jir_short_summary":"The share transfer execution date has been changed from scheduled end of November 2026 to scheduled end of December 2026. The reason is to carefully confirm the transition process and secure sufficient preparation time. Impact on consolidated earnings guidance for the fiscal year ending March 2027 is minor; negative goodwill is expected to arise.","jir_summary":"### Details of the Change and Background\nRegarding the acquisition of shares of Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Co., Ltd. (wholly owned subsidiarization) and the transfer of marketing authorization, we have decided to change the share transfer execution date to the end of December 2026 (scheduled). The change is to allow both companies to carefully confirm the transition process and ensure a sufficient preparation period.\n\n### Outlook and Impact\nThis change of date is expected to have only a minor impact on the Company\u2019s consolidated earnings guidance for the fiscal year ending March 2027. In addition, negative goodwill is expected to arise as a result of the share acquisition; the amount of goodwill and the impact on earnings guidance will be promptly disclosed once details are finalized.","jir_financial_highlights":"Share transfer execution date: Before change: end of November 2026 (scheduled) \/ After change: end of December 2026 (scheduled) (Date change)\nImpact: Minor impact on consolidated earnings guidance for the fiscal year ending March 2027 (No change to guidance)\nGoodwill: Negative goodwill is expected to arise (New)","jir_category":"","jir_hashtags":"#TowaPharmaceutical, #ChangeInDisclosure, #ConsolidatedEarningsImpact","jir_key_figures":"Share transfer execution date: Before change end of November 2026 \u2192 After change end of December 2026\nImpact: Minor impact on consolidated earnings guidance for the fiscal year ending March 2027\nGoodwill: Negative goodwill expected to arise","jir_meta_title":"Towa Pharmaceutical Co., Ltd. \u2014 Notice of Change to Share Transfer Execution Date | Scheduled End of December 2026","jir_meta_description":"The share transfer execution date for the acquisition of Tanabe Pharma Factory shares has been changed to the end of December 2026. Impact on consolidated earnings for the fiscal year ending March 2027 is expected to be minor. Negative goodwill is also expected.","jir_og_title":"Towa Pharmaceutical Co., Ltd. \u2014 Notice of Change to Share Transfer Date","jir_og_description":"The share transfer execution date has been changed to the end of December 2026 to secure the transition period. Negative goodwill is expected; further details will be announced.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9026,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-138895","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n